Results 171 to 180 of about 43,753 (301)

MDSCs come at a cost [PDF]

open access: yesNature Reviews Immunology, 2011
openaire   +1 more source

The Paediatric BCG Vaccine Century: From Historical Success to Future Innovations

open access: yesActa Paediatrica, EarlyView.
ABSTRACT Aim The tuberculosis (TB) vaccine, Bacille‐Calmette‐Guérin (BCG), protects infants against severe forms of primary TB. Yet, it does not protect against pulmonary reactivation TB in adults. Methods A literature review was conducted between 1st January and 28th February 2025 using PubMed, Google Scholar and reports of the World Health ...
Stefan H. E. Kaufmann
wiley   +1 more source

A murine model of sepsis induces age- and sex-specific chromatin remodeling in myeloid-derived suppressor cells. [PDF]

open access: yesFront Immunol
Charles AM   +20 more
europepmc   +1 more source

Circulating tumour cells (CTCs) in haematological malignancies: Advances in biology and clinical relevance with a focus on multiple myeloma

open access: yesBritish Journal of Haematology, EarlyView.
Spatial heterogeneity limits the sensitivity of bone marrow biopsies, resulting in false‐negative findings. Circulating tumour cells (CTCs) provide a systemic, stratified monitoring approach, using flow cytometry for high tumour burden and EuroFlow or allele‐specific oligonucleotide PCR (ASO‐PCR) for minimal residual disease to enable early relapse ...
Chin‐Mu Hsu   +3 more
wiley   +1 more source

High frequency of CD95+/CD45RA− regulatory T cells defines an immunosuppressive profile associated with MDS progression

open access: yesBritish Journal of Haematology, EarlyView.
Summary Dynamic interactions between mutated haematopoietic cells and immune cells are key drivers of myelodysplastic neoplasms (MDS) initiation and progression. Regulatory T cells (Tregs) are central mediators of immunosuppression in MDS. We thus aimed to characterize Treg subpopulations in the bone marrow (BM) of MDS patients and to explore their ...
Romain Vazquez   +18 more
wiley   +1 more source

Therapeutic potential of natural products in cancer immunotherapy: Advances and challenges

open access: yesBritish Journal of Pharmacology, EarlyView.
This review systematically outlines the mechanisms underlying tumour immunotherapy resistance and elucidates the role of natural products in enhancing therapeutic efficacy as immunomodulatory adjuvants. Abstract Immunotherapy has emerged as a clinically pivotal approach in cancer treatment, but its application remains limited to a small subset of ...
Rao Hu   +6 more
wiley   +1 more source

Cancer pain: current practice and emerging targets

open access: yesBritish Journal of Pharmacology, EarlyView.
Cancer pain (CP) arises from a complex interplay between the tumour and its microenvironment. Many patients experience a mixed pain phenotype that encompasses nociceptive, neuropathic and neuroinflammatory mechanisms, and vary across tumour type and disease stage. Despite decades of intensive research, the mainstay of cancer pain treatment is still non‐
Yi Ye   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy